Corcept Therapeutics, Inc.

As of October 10, 2025, Corcept Therapeutics, Inc. shows a mildly bullish trend, with mixed MACD signals and consistent mildly bullish indicators across various time frames, despite a recent 1-week return of -16.10% and strong year-to-date and 1-year performances of 46.78% and 63.45%, respectively.

As of October 10, 2025, Corcept Therapeutics shows a mildly bullish trend with mixed signals from MACD indicators and recent performance, having outperformed the S&P 500 significantly over the long term despite a recent 16.10% decline.

As of July 1, 2025, Corcept Therapeutics, Inc. has a mildly bullish technical trend, supported by strong moving averages and Bollinger Bands, despite mixed signals from the MACD and RSI.

As of August 4, 2025, Corcept Therapeutics, Inc. is considered very expensive due to high valuation ratios, including a P/E of 59 and an EV to EBITDA of 66.34, despite strong stock performance that significantly outpaced the S&P 500.

As of March 31, 2025, Corcept Therapeutics, Inc. is considered overvalued with a P/E ratio of 59 and an EV/EBITDA ratio of 66.34, both significantly higher than industry averages, despite strong operational efficiency metrics.

As of June 18, 2025, the trend is mildly bullish with mixed signals, as monthly MACD shows bullish momentum while weekly indicators are mildly bearish, suggesting a cautiously optimistic outlook.

As of March 2022, the management team of Corcept Therapeutics, Inc. includes Mr. James Wilson (Independent Chairman), Dr. Joseph Belanoff (CEO), Dr. Gillian Cannon, and several independent directors: Mr. Gregg Alton, Mr. George Baker, Mr. David Mahoney, and Ms. Kimberly Park. They oversee the company's strategic direction and operations.

Corcept Therapeutics, Inc. is a pharmaceutical company focused on developing drugs for severe metabolic, psychiatric, and oncologic disorders. As of March 2025, it reported net sales of $157 million and a net profit of $20 million, with a market cap of approximately $8.04 billion.

As of Jun 18, Corcept Therapeutics, Inc. has a market capitalization of $8.04 billion, with net sales of $685.45 million and a net profit of $132.49 million over the last four quarters.